GlassScriptPhysician profile
Daniel Wubneh
NPI 1407174923
$17,677.07
in general payments reported to CMS, 2019-2025
31 companies · $5,363 in 2025
The $5,363 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,715 · 2020: $634 · 2021: $1,034 · 2022: $5,627 · 2023: $1,879 · 2024: $1,424 · 2025: $5,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,231 · Travel and Lodging: $3,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,231.00 |
| Travel and Lodging | $3,435.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,472.88 | 2021-2025 | Farapulse, General - Therapies, Watchman Flx |
| Medtronic, INC. | $2,225.77 | 2021-2022 | |
| Artivion, INC. | $1,226.27 | 2019 | |
| Abbott Laboratories | $721.59 | 2020-2025 | Amplatzer Amulet, Mitraclip, Aveir |
| Novartis Pharmaceuticals Corporation | $689.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $544.57 | 2019-2024 | Camzyos, Eliquis |
| Pfizer INC. | $418.75 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $367.81 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $340.78 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $335.52 | 2020-2025 | Farxiga |
| Esperion Therapeutics, INC. | $286.06 | 2021-2023 | Nexletol |
| Edwards Lifesciences Corporation | $254.88 | 2021-2024 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.93 | 2022-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $203.13 | 2020-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $183.67 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $164.69 | 2020-2021 | |
| Cvrx, INC. | $139.12 | 2023 | Barostim Neo System |
| Medtronic Vascular, INC. | $126.11 | 2019 | |
| Akcea Therapeutics, INC. | $125.00 | 2020 | |
| La Jolla Pharmaceutical Company | $124.80 | 2025 | Zevtera |
| Abiomed | $112.36 | 2024 | Impella |
| W. L. Gore & Associates, INC. | $109.42 | 2023 | Gore Cardioform Septal Occluder |
| Amarin Pharma, INC. | $64.97 | 2020-2022 | |
| Depuy Synthes Sales INC. | $55.62 | 2024 | Matrixrib |
| Novo Nordisk INC | $39.07 | 2022-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $33.61 | 2022 | |
| Alnylam Pharmaceuticals INC. | $21.60 | 2025 | Amvuttra |
| Irhythm Technologies, INC. | $18.97 | 2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals, LTD. | $16.80 | 2021 | |
| Daiichi Sankyo INC. | $15.97 | 2020 | |
| Davol INC. | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wubneh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.